$1.62
1.25% today
Nasdaq, Apr 04, 09:16 pm CET
ISIN
US4380831077
Symbol
QTTB
Sector
Industry

Homology Medicines, Inc. Stock price

$1.60
-0.56 25.93% 1M
-41.15 96.26% 6M
-1.84 53.49% YTD
-19.69 92.48% 1Y
-54.56 97.15% 3Y
-297.92 99.47% 5Y
-334.28 99.52% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
+0.12 7.74%
ISIN
US4380831077
Symbol
QTTB
Sector
Industry

Key metrics

Market capitalization $19.52m
Enterprise Value $-39.55m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 3.44
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-66.10m
Cash position $77.97m
EPS (TTM) EPS $-10.37
Short interest 0.04%
Show more

Is Homology Medicines, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Homology Medicines, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Homology Medicines, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a Homology Medicines, Inc. forecast:

Buy
33%
Hold
67%

Financial data from Homology Medicines, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.49 0.49
62% 62%
-
-0.49 -0.49
277% 277%
-
- Selling and Administrative Expenses 17 17
41% 41%
-
- Research and Development Expense 48 48
22% 22%
-
-66 -66
28% 28%
-
- Depreciation and Amortization 0.49 0.49
62% 62%
-
EBIT (Operating Income) EBIT -66 -66
28% 28%
-
Net Profit -48 -48
58% 58%
-

In millions USD.

Don't miss a Thing! We will send you all news about Homology Medicines, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Homology Medicines, Inc. Stock News

Neutral
PRNewsWire
24 days ago
-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-breaking oral presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting -- -- Advancing bempikibart in patients with AA, with SIGNAL-AA open-label extension (OLE) and SIGNAL-AA Part ...
Neutral
PRNewsWire
27 days ago
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very severe alopecia areata (AA) -- -- Durable, ongoing responses in multiple patients through week 36 follow-up period and beyond to week 55, despite only 24 weeks of dosing, suggestive of potential for ...
Neutral
PRNewsWire
about one month ago
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM, Mass. , Feb. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune ...
More Homology Medicines, Inc. News

Company Profile

Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.

Head office United States
CEO Jodie Morrison
Employees 42
Founded 2015
Website www.q32bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today